Pharma frustrated by Turkey's drug registration delays
This article was originally published in Scrip
Executive Summary
Some 476 innovator pharmaceutical products, including new anticancers and diabetes drugs, are still waiting to be registered in Turkey, meaning delays to patients, as the authorities try to find the resources to inspect some 261 manufacturing plants outside the country to meet a GMP requirement that was introduced in December 2009.